Načítá se...
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2001
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC59641/ https://ncbi.nlm.nih.gov/pubmed/11806792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cvm-2-4-171 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|